1. Home
  2. CAST vs LONA Comparison

CAST vs LONA Comparison

Compare CAST & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FreeCast Inc. Class A Common Stock

CAST

FreeCast Inc. Class A Common Stock

N/A

Current Price

$1.42

Market Cap

65.2M

Sector

Technology

ML Signal

N/A

Logo LeonaBio Inc. Common Stock

LONA

LeonaBio Inc. Common Stock

N/A

Current Price

$6.70

Market Cap

71.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAST
LONA
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.2M
71.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CAST
LONA
Price
$1.42
$6.70
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$6.00
$10.00
AVG Volume (30 Days)
1.3M
38.3K
Earning Date
06-26-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$4.21
52 Week High
$12.20
$14.21

Technical Indicators

Market Signals
Indicator
CAST
LONA
Relative Strength Index (RSI) 48.23 47.88
Support Level $1.24 $6.86
Resistance Level $1.55 $8.57
Average True Range (ATR) 0.12 0.66
MACD 0.04 -0.04
Stochastic Oscillator 64.52 37.79

Price Performance

Historical Comparison
CAST
LONA

About CAST FreeCast Inc. Class A Common Stock

FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and streaming services.

About LONA LeonaBio Inc. Common Stock

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Share on Social Networks: